Humacyte/$HUMA
1D1W1MYTD1Y5YMAX
Capital at risk
About Humacyte
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
- Ticker
- $HUMA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 184
- Headquarters
- Durham, United States
- Website
- www.humacyte.com
Humacyte Metrics
BasicAdvanced
$165M
-
-$0.50
2.47
-
Price and volume
Market cap
$165M
Beta
2.47
52-week high
$2.55
52-week low
$0.53
Average daily volume
7.8M
Financial strength
Current ratio
6.207
Quick ratio
5.367
Long term debt to equity
206.846
Total debt to equity
213.941
Interest coverage (TTM)
-6.97%
Profitability
EBITDA (TTM)
-103.228
Gross margin (TTM)
-3,742.29%
Net profit margin (TTM)
-4,560.82%
Operating margin (TTM)
-5,207.78%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-49.87%
Return on equity (TTM)
-547.87%
Valuation
Price to revenue (TTM)
54.543
Price to book
5.29
Price to tangible book (TTM)
5.29
Price to free cash flow (TTM)
-1.186
Free cash flow yield (TTM)
-84.34%
Free cash flow per share (TTM)
-0.502
Growth
Revenue change (TTM)
159.29%
Earnings per share change (TTM)
12.92%
3-year revenue growth (CAGR)
309.00%
3-year earnings per share growth (CAGR)
-16.65%
What the Analysts think about Humacyte
Analyst ratings (Buy, Hold, Sell) for Humacyte stock.
Analyst projections of the future price of Humacyte stock.
Humacyte Financial Performance
Revenues and expenses
Humacyte Earnings Performance
Company profitability
Upcoming events
No upcoming events
Humacyte News
AllArticlesVideos
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
Business Wire6 days ago
Humacyte Q2 Earnings Call Highlights
MarketBeat4 weeks ago
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
Business Wire1 month ago
Funds containing Humacyte
AllUSDGBP
Fund name | Fund size | $HUMA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.01% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.